Tessera Therapeutics
Aimee Tallarico has extensive work experience in the field of operations and research. Aimee currently holds the position of Senior Director of Operations at Tessera Therapeutics since March 2021. Prior to that, they worked as Associate Director of Operations at Editas Medicine from February 2018 to March 2021. Aimee also served as Associate Director of Operations at Mitobridge, Inc. from December 2014 to January 2018. Their earliest work experience was as a researcher at the Dana-Farber Cancer Institute, where they worked from an unknown start date until December 2014.
Aimee Tallarico holds a Ph.D. in Bioorganic Chemistry from Boston College and a Bachelor of Arts degree in Chemistry from Mount Holyoke College.
Tessera Therapeutics
3 followers
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.